Immunotherapy Toxicities.

Publication Title

Surgical oncology clinics of North America

Authors

Katherine Sanchez, Earle A. Chiles Research Institute, Portland, OR; Providence Cancer Institute, Portland, ORFollow
David B Page, Providence Cancer Center, Earle A. Chiles Research Institute Portland , OR , USAFollow
Walter Urba, Earle A. Chiles Research Institute, Providence Cancer Center, Portland, OR, 97213, USA.Follow

Document Type

Article

Publication Date

7-1-2019

Keywords

Immune checkpoint inhibitors side effects; Immune-related adverse events (irAE); Mechanisms of irAE; T cell mediated toxicity

Abstract

Immune checkpoint inhibitors (ICIs) are therapeutic antibodies that target regulatory molecules on T cells and represent the most widely used FDA-approved class of immunotherapy. ICIs are associated with unique immune-mediated toxicities called immune-related adverse events. These toxicities may affect any organ system, and their precise mechanisms of action remain under investigation. Current evidence suggests that activation of T cells is involved, although other components of the immune response have been implicated. This article summarizes toxicities, potential mechanisms of action, management strategies, and other clinical considerations. Unique mechanisms of action and immune-related toxicities of other FDA-approved classes of immunotherapy are reviewed.

Clinical Institute

Cancer

Specialty/Research Institute

Earle A. Chiles Research Institute

Specialty/Research Institute

Oncology